ABSTRACT Tumor heterogeneity and immunosuppression limit the efficacy of conventional immunotherapy. Here, we introduce a spatiotemporally engineered nanoplatform ( CAP/CyOH@NPs ) that achieves multi‐organelle targeting in tumor cells through POSS‐based nanoconfinement. The rigid POSS cage co‐encapsulates a photothermal agent (CyOH) and chemotherapeutic prodrug (capecitabine), enabling stable, simultaneous localization to lysosomes, mitochondria, and the endoplasmic reticulum‐independent of pH or membrane potential. This subcellular precision enhances photothermal conversion (53.4%) and amplifies immunogenic cell death via coordinated organelle stress. When combined with PD‐L1 blockade, the platform remodels the tumor immune microenvironment and suppresses both primary and distant tumors in a 4T1 breast cancer model. This work establishes a new paradigm for engineering nanomedicines with organelle‐level specificity, offering a versatile strategy to overcome resistance in precision oncology.
Building similarity graph...
Analyzing shared references across papers
Loading...
Xiaoying Ma
Hangzhou Normal University
Yang Li
Sina Chen
Hangzhou Normal University
Advanced Healthcare Materials
Donghua University
Hangzhou Normal University
Fuyang Normal University
Building similarity graph...
Analyzing shared references across papers
Loading...
Ma et al. (Thu,) studied this question.
synapsesocial.com/papers/696c776ceb60fb80d1395b60 — DOI: https://doi.org/10.1002/adhm.202505008
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: